In adults with type 2 diabetes who had a myocardial infarction, the risk of cardiovascular death or heart failure hospitalisation was not significantly lower with liraglutide (23.0%) than with placebo (26.7%).
In plain wordsIn adults with type 2 diabetes who had a heart attack, liraglutide did not significantly lower later heart death or heart failure admissions versus placebo.
- Peptide
- Liraglutide
- Outcome
- No significant changeCardiovascular death or heart failure hospitalisation after myocardial infarction
- Study
n: not reported in source
- Comparator
- Placebo
- Outcome group
- Cardiovascular events · Cardiovascular
- Studied dose
- Dose not stated
Measurements
- Hazard ratio
- 0.91 HR
- liraglutide vs placebo, 95% CI 0.66-1.26
Source sentences
The risk of the composite endpoint after myocardial infarction was not significantly lower in the liraglutide group ( n = 63, 23.0%) compared with placebo ( n = 85, 26.7%; hazard ratio: 0.91; 95% confidence interval: 0.66, 1.26).
1 context sentence(design, population, supporting numbers)
Data from patients randomised to liraglutide or placebo, in addition to standard of care, in Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) (NCT01179048) were analysed post hoc.